#1 Clinical Trials Search in Europe

Prasugrel

Prasugrel is an antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention (PCI). This article summarizes key findings from clinical trials investigating the use of prasugrel in various cardiovascular conditions, its pharmacokinetics, and comparisons to other antiplatelet drugs.

Table of Contents

What is Prasugrel?

Prasugrel is a medication used to prevent blood clots in people with certain heart conditions. It belongs to a class of drugs called antiplatelet agents or thienopyridines. Prasugrel is known by several brand names, including Effient, Efient, and in some cases, Prasita[1]. Other names you might hear include LY640315 and CS-747[2].

How Prasugrel Works

Prasugrel works by preventing platelets (small blood cells that help your blood clot) from sticking together and forming clots. It does this by blocking a specific receptor on platelets called P2Y12. When you take prasugrel, your body converts it into an active form that can effectively inhibit platelet aggregation (clumping together)[3].

Conditions Treated with Prasugrel

Prasugrel is primarily used to treat and prevent complications in patients with:

  • Acute Coronary Syndrome (ACS): This is a term used for situations where the blood supply to the heart muscle is suddenly blocked or severely reduced[4].
  • Coronary Artery Disease: A condition where the arteries that supply blood to the heart become narrowed or blocked[5].
Prasugrel is often prescribed for patients who have undergone a procedure called percutaneous coronary intervention (PCI), which is a non-surgical procedure used to open blocked coronary arteries[3].

Dosage and Administration

Prasugrel is typically given in two phases:

  1. Loading dose: A higher initial dose to quickly achieve the desired effect. This is often 60 mg taken as a single dose[3].
  2. Maintenance dose: A lower daily dose to maintain the effect. This is usually 10 mg per day[3].
However, the exact dosage can vary depending on factors such as your weight, medical condition, and response to treatment. Always follow your doctor’s instructions regarding dosage[1].

Effectiveness of Prasugrel

Studies have shown that prasugrel can be more effective than some other antiplatelet medications, such as clopidogrel, in preventing blood clots and reducing the risk of heart attacks in certain patients. It tends to work faster and provide more consistent platelet inhibition[3].

Potential Side Effects

Like all medications, prasugrel can cause side effects. The most significant risk is bleeding, which can sometimes be severe. This is because the medication’s action of preventing blood clots also makes it easier for you to bleed. Other potential side effects may include:

  • Bruising more easily
  • Nosebleeds
  • Stomach pain or discomfort
  • Headache
It’s important to discuss any side effects you experience with your healthcare provider[4].

Use in Special Populations

Prasugrel is being studied in various patient groups:

  • Pediatric patients: Research is ongoing to determine the correct dosage and effectiveness of prasugrel in children with certain conditions, such as sickle cell disease[6].
  • Patients with sickle cell disease: Studies are investigating whether prasugrel could be beneficial for adults with this condition[2].
Always inform your doctor about all your medical conditions and medications to ensure prasugrel is safe and appropriate for you.

Ongoing Research

Researchers continue to study prasugrel to understand its effects better and explore new potential uses. Some areas of ongoing research include:

  • Comparing different dosing strategies[7]
  • Investigating its effects when given in crushed form[5]
  • Exploring its potential benefits in conditions like asthma[8]
These studies help healthcare providers better understand how to use prasugrel effectively and safely in different patient populations.

Aspect Details
Primary Uses Prevention of blood clots in ACS patients and those undergoing PCI
Common Dosages Loading dose: 30-60 mg; Maintenance dose: 5-15 mg daily
Comparison to Clopidogrel Generally more effective in preventing ischemic events, but may have higher bleeding risk
Special Populations Studied in pediatric sickle cell disease patients and ACS patients; dosing adjustments may be needed for certain groups
Efficacy Measurements Platelet reactivity tests (VerifyNow P2Y12, light transmission aggregometry, VASP assay)
Safety Considerations Bleeding risk, particularly in patients with low body weight or higher bleeding risk factors
Pharmacokinetic Studies Focused on absorption, distribution, and metabolism of prasugrel and its active metabolite
Formulation Studies Investigations into crushed tablets for potentially faster onset of action

FAQ

  • What is prasugrel used for? Prasugrel is primarily used to prevent blood clots in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention (PCI). It helps reduce the risk of heart attacks and strokes in these patients.
  • How does prasugrel compare to clopidogrel? Studies have shown that prasugrel is generally more effective than clopidogrel in preventing ischemic events in patients with ACS undergoing PCI. However, prasugrel may also have a higher risk of bleeding compared to clopidogrel.
  • What are the typical dosages of prasugrel used in clinical trials? Clinical trials have investigated various dosages of prasugrel, including loading doses of 30 mg, 40 mg, and 60 mg, followed by maintenance doses ranging from 5 mg to 15 mg daily. The most common regimen studied was a 60 mg loading dose followed by a 10 mg daily maintenance dose.
  • Are there any special considerations for prasugrel use in certain populations? Yes, some trials have investigated prasugrel use in specific populations such as pediatric patients with sickle cell disease and patients with acute coronary syndrome. Dosing adjustments may be necessary for certain groups, such as patients weighing less than 60 kg or those with a higher bleeding risk.
  • What are some common methods used to measure prasugrel's effectiveness in clinical trials? Clinical trials often use various methods to assess prasugrel's effectiveness, including measuring platelet reactivity through tests like VerifyNow P2Y12 assay, light transmission aggregometry, and vasodilator-stimulated phosphoprotein (VASP) assay. These tests help determine the level of platelet inhibition achieved by prasugrel.

Ongoing Clinical Trials on Prasugrel

  • Study comparing high-dose and low-dose aspirin with prasugrel and aspirin combination in patients after coronary artery bypass grafting surgery

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Reduced Dose Prasugrel Monotherapy After Stent Placement in Patients with Acute and Chronic Coronary Syndrome

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety and Effectiveness of Short Dual Antiplatelet Therapy with Ticagrelor, Clopidogrel, and Prasugrel in Patients Aged 65+ with Coronary Artery Disease

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Prasugrel and Acetylsalicylic Acid for Patients with ST-Elevated Myocardial Infarction Undergoing Different Revascularization Techniques

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Germany Italy The Netherlands

  • Study on the Effects of Ticagrelor and Rivaroxaban in Patients with Atrial Fibrillation After Coronary Stent Surgery

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study on Adjusting Clopidogrel and Prasugrel Dosage for Patients with Chronic Coronary Syndrome Based on Body Weight

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness of Clopidogrel, Prasugrel, and Ticagrelor in Patients with Coronary Acute Syndrome Using VerifyNow Device

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Reducing Antiplatelet Therapy in Patients with Acute Coronary Syndrome and High Bleeding Risk Using Prasugrel, Ticagrelor, or Clopidogrel

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Personalized Antithrombotic Therapy with Acenocoumarol, Phenprocoumon, and Apixaban for Patients with Aortic Valve Stenosis Post-TAVI

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany The Netherlands

  • Study Comparing Drug-Coated Balloon and Drug-Eluting Stents in Patients with Coronary Artery Disease at High Risk of Bleeding Using Acetylsalicylic Acid and Drug Combination

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland France Spain

Glossary

  • Acute Coronary Syndrome (ACS): A group of conditions that suddenly reduce blood flow to the heart, including unstable angina and heart attacks.
  • Percutaneous Coronary Intervention (PCI): A non-surgical procedure used to open blocked coronary arteries, often involving the placement of a stent.
  • Loading Dose (LD): An initial higher dose of medication given to quickly achieve therapeutic levels in the body.
  • Maintenance Dose (MD): The regular, lower dose of medication given after the loading dose to maintain therapeutic levels.
  • Platelet Aggregation: The clumping together of platelets in the blood, which is part of the blood clotting process.
  • P2Y12 Inhibitor: A class of antiplatelet drugs that block the P2Y12 receptor on platelets, reducing their ability to form clots.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body.
  • Major Adverse Cardiovascular Events (MACE): A composite endpoint in clinical trials that typically includes events such as death, heart attack, and stroke.
  • Thrombolysis In Myocardial Infarction (TIMI) Bleeding Criteria: A standardized method for classifying the severity of bleeding events in clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT01591317
  2. https://clinicaltrials.gov/study/NCT01178099
  3. https://clinicaltrials.gov/study/NCT01505790
  4. https://clinicaltrials.gov/study/NCT03672097
  5. https://clinicaltrials.gov/study/NCT02212028
  6. https://clinicaltrials.gov/study/NCT01476696
  7. https://clinicaltrials.gov/study/NCT01365221
  8. https://clinicaltrials.gov/study/NCT01305369